IPO Plans for Adimmune Corp., in Central Taiwan Science Park (CTSP)



Adimmune Corp., a Taiwanese vaccine manufacturer, could be listed on the Taiwan Stock Exchange in March at the earliest, a company official said Monday.

Adimmune Chairman Chan Chi-shean made the remarks after the Taiwan Stock Exchange Corp. (TWSE) approved its application.

The company also announced several steps forward in its business, including the completion of clinical testing of influenza vaccine in Europe with Netherlands-based Crucell, with which Adimmune has an alliance.

The H5N1 vaccine, which completed animal testing late last year, is scheduled to go into human testing in the second quarter this year at the earliest.

In addition, the company’s cell culture plant in the Central Taiwan Science Park (CTSP) is expected to complete construction in 2014 and to start production in 2015.

Adimmune signed an agreement with the CTSP last December to establish the plant at the Taichung-based park, under which Adimmune would invest NT$3 billion (US$101.38 million) and provide enterovirus vaccine in the initial stage, and vaccines for Japanese encephalitis, dengue fever and various animal diseases in the medium- and long-term.

For article reference Click Here.

The Central Taiwan Science Park (CTSP) is a Featured Park.  For more information Click Here.





Leave a Reply

You must be logged in to post a comment.